NEU 8.52% $14.40 neuren pharmaceuticals limited

2017...2018?, page-4

  1. 183 Posts.
    lightbulb Created with Sketch. 99
    WAG,
    In my opinion, that's a good point you make with regards to "relatively low cost" P3 surprise for the board and if this is the case then we need a CR, because money from Lanstead is not enough. I am thinking that we need around $30-35 mils, in addition to $11-12 mils (at current price) from Lanstead to be on the safe side and get through P3. The question mark is the CR share price, I believe there are willing institutional investors to take the relatively low-medium risks and come up with the money. If the issue share price is in this $3-3.30 range which is not necessarily unheard of in comparison with the current share price (but is also wishful thinking from me) then I would personally support such an approach rather than sell the company for $6-7/share - I believe there are currently such T/O offers on table - and cut any upside from the future.
    $35 mil @ $3 means 11.6 mil shares which is not a high percentage dilution and acceptable for me in order to go alone to P3 and have all the upside from a successful P3
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$14.40
Change
1.130(8.52%)
Mkt cap ! $1.840B
Open High Low Value Volume
$13.80 $14.45 $13.53 $15.04M 1.062M

Buyers (Bids)

No. Vol. Price($)
1 871 $14.39
 

Sellers (Offers)

Price($) Vol. No.
$14.42 3650 3
View Market Depth
Last trade - 16.10pm 07/11/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.